David Pass | Obesity, Type 2 Diabetes, and Next-Generation Cardiometabolic Therapies
David Pass joins Executive Insights for Life Sciences Innovators to discuss obesity, type 2 diabetes, cardiometabolic disease, and the development of differentiated therapies designed to address persistent gaps in patient care.
Prefer audio only? Listen to this episode on Spotify.
Episode Overview
In this episode, David Pass discusses how AltrixBio is developing AJN003, a novel oral, gut-targeted therapy inspired by the metabolic effects observed following bariatric surgery. The conversation explores the evolving treatment landscape for obesity and type 2 diabetes, the limitations of current therapies, and the challenges of advancing differentiated cardiometabolic innovations toward the clinic.
Key Themes
- Novel therapies for type 2 diabetes and obesity
- Gut-targeted approaches to cardiometabolic disease
- AJN003 and bariatric surgery-inspired innovation
- Opportunities and limitations of GLP-1 therapies
- Advancing differentiated science in competitive markets
- Leadership and strategy in cardiometabolic biotechnology
Why This Matters for Life Sciences Leaders
Despite significant advances in obesity and diabetes treatment, substantial unmet needs remain for patients requiring effective, accessible, and durable therapeutic options. The conversation highlights how biotechnology companies are pursuing new mechanisms and treatment approaches while navigating the scientific, clinical, and commercial challenges of bringing differentiated therapies to market. It also provides valuable insights into leadership, innovation, and strategic execution in one of the most active areas of life sciences today.
Guest Link
More from Executive Insights
Explore more conversations with life sciences founders, CEOs, investors, and operators on the Executive Insights for Life Sciences Innovators podcast.
